NephroDI Therapeutics Analysis: $4M Raised
What is NephroDI Therapeutics?
Pharmaceutical company targeting nephrogenic diabetes insipidus
Location
Seattle, United States
Employees
1-10
Founded
2017
Product Features & Capabilities
- Oral drug for nephrogenic diabetes insipidus
- Research on AMPK therapy
Use Cases
Treat children with nephrogenic diabetes insipidus; Address severe dehydration in NDI patients; Develop therapies for congenital NDI; Research genetic mutations affecting vasopressin receptors; Collaborate with strategic partners for drug development
Other Considerations
Announced leadership appointments including Dr. Jeff Sands as Chief Medical Officer; Entered agreement with MSRD and Otsuka for NDI treatment development
See something that needs updating? Suggest edits to this profile.